WO2000071106A3 - Method of treating weight gain - Google Patents

Method of treating weight gain Download PDF

Info

Publication number
WO2000071106A3
WO2000071106A3 PCT/GB2000/001875 GB0001875W WO0071106A3 WO 2000071106 A3 WO2000071106 A3 WO 2000071106A3 GB 0001875 W GB0001875 W GB 0001875W WO 0071106 A3 WO0071106 A3 WO 0071106A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight gain
treating weight
treating
psychoses
administering
Prior art date
Application number
PCT/GB2000/001875
Other languages
French (fr)
Other versions
WO2000071106A2 (en
Inventor
Michael J Reinstein
Andrew Martin Jones
Original Assignee
Astrazeneca Ab
Michael J Reinstein
Andrew Martin Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911499.3A external-priority patent/GB9911499D0/en
Priority claimed from GB0002762A external-priority patent/GB0002762D0/en
Application filed by Astrazeneca Ab, Michael J Reinstein, Andrew Martin Jones filed Critical Astrazeneca Ab
Priority to AU45984/00A priority Critical patent/AU4598400A/en
Priority to EP00927593A priority patent/EP1223939A1/en
Priority to CA002363784A priority patent/CA2363784A1/en
Priority to JP2000619413A priority patent/JP2003500353A/en
Publication of WO2000071106A2 publication Critical patent/WO2000071106A2/en
Publication of WO2000071106A3 publication Critical patent/WO2000071106A3/en
Priority to HK02109422.7A priority patent/HK1048440A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

A method of treating weight in patients, in particular those suffering from psychoses, by administering the antipsychotic agent quetiapine.
PCT/GB2000/001875 1999-05-19 2000-05-16 Method of treating weight gain WO2000071106A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU45984/00A AU4598400A (en) 1999-05-19 2000-05-16 Method of treatment
EP00927593A EP1223939A1 (en) 1999-05-19 2000-05-16 Method of treating weight gain
CA002363784A CA2363784A1 (en) 1999-05-19 2000-05-16 Method of treatment
JP2000619413A JP2003500353A (en) 1999-05-19 2000-05-16 Treatment method
HK02109422.7A HK1048440A1 (en) 1999-05-19 2002-12-30 Method of treating weight gain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9911499.3 1999-05-19
GBGB9911499.3A GB9911499D0 (en) 1999-05-19 1999-05-19 Medicament
GB0002762A GB0002762D0 (en) 2000-02-08 2000-02-08 Method of treatment
GB0002762.3 2000-02-08

Publications (2)

Publication Number Publication Date
WO2000071106A2 WO2000071106A2 (en) 2000-11-30
WO2000071106A3 true WO2000071106A3 (en) 2002-05-10

Family

ID=26243587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001875 WO2000071106A2 (en) 1999-05-19 2000-05-16 Method of treating weight gain

Country Status (6)

Country Link
EP (1) EP1223939A1 (en)
JP (1) JP2003500353A (en)
AU (1) AU4598400A (en)
CA (1) CA2363784A1 (en)
HK (1) HK1048440A1 (en)
WO (1) WO2000071106A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062346A1 (en) * 2001-02-06 2002-08-15 Astrazeneca Ab Method of treating substance abuse with quetiapine
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
EP1408981B1 (en) * 2001-07-23 2008-08-27 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
BRPI0506807A (en) * 2004-04-22 2007-05-29 Mor Research Applic Ltd food consumption management method and pharmacological composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032037A1 (en) * 1996-03-01 1997-09-04 Smithkline Beecham Plc Assessment of the responsiveness of individuals to modulators of the 5-ht2 receptors, especially the 5-ht2a receptor
WO1998004289A2 (en) * 1996-07-26 1998-02-05 Smithkline Beecham Plc Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2000054764A2 (en) * 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032037A1 (en) * 1996-03-01 1997-09-04 Smithkline Beecham Plc Assessment of the responsiveness of individuals to modulators of the 5-ht2 receptors, especially the 5-ht2a receptor
WO1998004289A2 (en) * 1996-07-26 1998-02-05 Smithkline Beecham Plc Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2000054764A2 (en) * 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.", JOURNAL OF CLINICAL PSYCHIATRY, (1998) 59 SUPPL 12 17-22. REF: 57, XP001009550 *
LEYSEN J.E. ET AL: "Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects.", INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, (1998) 2/SUPPL. 1 (S3-S17)., XP001009585 *
MISRA L K ET AL: "Quetiapine: a new atypical antipsychotic.", SOUTH DAKOTA JOURNAL OF MEDICINE, (1998 JUN) 51 (6) 189-93. REF: 13, XP000901163 *
NASR S J: "Resolution of rapid weight gain on olanzapine after substitution with quetiapine.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 10, no. Supplement 3, September 2000 (2000-09-01), 13th Congress of the European College of Neuropsychopharmacology;Munich, Germany; September 09-13, 2000, pages S319, XP001009548, ISSN: 0924-977X *
REINSTEIN MICHAEL J ET AL: "Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: Preliminary findings.", CLINICAL DRUG INVESTIGATION, vol. 18, no. 2, August 1999 (1999-08-01), pages 99 - 104, XP001009552, ISSN: 1173-2563 *
ROBERTSON J B JR ET AL: "Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapine.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 10, no. Supplement 3, September 2000 (2000-09-01), 13th Congress of the European College of Neuropsychopharmacology;Munich, Germany; September 09-13, 2000, pages S319 - S320, XP001010838, ISSN: 0924-977X *

Also Published As

Publication number Publication date
WO2000071106A2 (en) 2000-11-30
HK1048440A1 (en) 2003-04-04
EP1223939A1 (en) 2002-07-24
CA2363784A1 (en) 2000-11-30
JP2003500353A (en) 2003-01-07
AU4598400A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
AU5722800A (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
GB2347703B (en) Emergency well kill method
ZA200108446B (en) Novel method of treatment.
AU3357500A (en) Method for intravascular radiation therapy
MXPA02005735A (en) Enzyme treatment for infection.
AU3162001A (en) Medicament, a method for its production and the use thereof
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU773240C (en) Medicament for treating hypertension
WO2001041751A8 (en) Phytoestrogens for treating als
AU2042301A (en) 1-aminoalkyl-1H-indoles for treating glaucoma
MXPA01008512A (en) A method for treatment of wool.
ZA200105690B (en) Novel treatment.
WO2000071106A3 (en) Method of treating weight gain
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
AU6726700A (en) Method of treating 1,1,1,3,3-pentafluoropropane
AU6328700A (en) Method for immobilising physiologically active compounds
AU5585700A (en) Process for making 2,4,6, 8,10,12- hexanitro- 2,4,6,8,10, 12- hexa azatetracyclo(5.5.0. 05,9.03,11} -dodecane
WO1999053064A3 (en) Methods of delivering glp-1
AU6332700A (en) Municipal waste-water treatment method
ZA200003235B (en) Combination therapy for the treatment of migraine.
WO2000047197A3 (en) Alkylating agents for treatment of cellular proliferation
EP1459748B8 (en) (S,S)-reboxetine for treating peripheral neuropathy
ZA991786B (en) Therapeutic treatment for asthma.
AU6438200A (en) Low-dose, soluble builder
AUPQ072899A0 (en) Denitrification process

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2363784

Country of ref document: CA

Ref country code: CA

Ref document number: 2363784

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619413

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000927593

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10009574

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000927593

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000927593

Country of ref document: EP